What type of patients do you accept?
We do not provide Parkinson’s disease care to the following patients:
- Institutionalized patients with Parkinson’s disease (nursing homes, etc.)
- Patients over 75 years old
- Patients who are taking traditional Parkinson's disease drugs with a total dosing value of L-dopa greater than 1,200 mg per day.
How is this protocol approach different?
Medicine recognizes L-dopa as the most effective Parkinson’s disease treatment available. All other approaches and not as effective. Our method of care is not new; we use the nutritional based active ingredient L-dopa. The difference is standard of care in medicine uses another drug packaged in combination with the L-dopa to manage problems that have plagued treatment with L-dopa for over 50 years (see below). The advantage of our approach is the ability to manage and eliminate these nutritional deficiency based problems and side effects induced by drug co-packaged with L-dopa. This approach is a nutritional deficiency approach, as such the FDA requires us to note that this approach does not cure, treat, mitigate, or prevent disease. Drugs can’t manage nutritional deficiencies.
What problems can depletion of vitamin B6 by traditional Parkinson's disease drugs cause?
- Induce relative nutritional deficiencies of vitamin B6.
- Interfere with vitamin B6 dependent processes.
- Can change dopamine precursors from a nutrient to a drug as side effect develop.
- Linked to the increasing death rate among Parkinson’s disease patients.
- Can make symptoms of Parkinson’s disease associated nutritional deficiencies worse.
- Can accelerate fat soluble neurotoxin-induced brain damage.
- Can cause dopamine depletion with an associated increase in symptoms.
- Can cause the nutrients required to make dopamine to quit working.
- Can induce what were previously thought to be permanent and irreversible dyskinesias and choreiform movement disorder during treatment.